Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
22 12 2021
Historique:
pubmed: 9 12 2021
medline: 9 2 2022
entrez: 8 12 2021
Statut: ppublish

Résumé

The clinical importance of Mycobacterium abscessus (MABS) pulmonary disease has been increasing. However, there is still a lack of information about MIC distribution patterns and changes in clinical practice settings. The MIC results of rapidly growing mycobacteria isolated from 92 patients with nontuberculous mycobacterial pulmonary disease diagnosed from May 2019 to March 2021 were retrospectively analyzed. Most of the patients (86 patients; 93.5%) were infected with MABS; 46 with Mycobacterium abscessus subsp.

Identifiants

pubmed: 34878300
doi: 10.1128/Spectrum.01928-21
pmc: PMC8653840
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azithromycin 83905-01-5
Clarithromycin H1250JIK0A

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0192821

Références

Am J Respir Crit Care Med. 2011 Feb 1;183(3):405-10
pubmed: 20833823
J Antimicrob Chemother. 2017 Nov 01;72(11):3070-3078
pubmed: 28961987
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28348153
Clin Infect Dis. 2020 Aug 14;71(4):905-913
pubmed: 32797222
Clin Chem. 2015 Jan;61(1):100-11
pubmed: 25278500
Eur Respir J. 2015 Apr;45(4):1177-9
pubmed: 25614169
Sci Rep. 2021 Jun 9;11(1):12208
pubmed: 34108590
J Antimicrob Chemother. 2014 Jun;69(6):1559-63
pubmed: 24500188
Int J Infect Dis. 2020 Aug;97:270-277
pubmed: 32526389
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28807911
J Infect Chemother. 2002 Sep;8(3):252-5
pubmed: 12373490
Biomed Res Int. 2015;2015:419392
pubmed: 26351633
J Clin Microbiol. 2019 Sep 24;57(10):
pubmed: 31315954
Open Forum Infect Dis. 2019 Mar 07;6(4):ofz108
pubmed: 31111076
Chest. 2021 Feb;159(2):517-523
pubmed: 32712225
Clin Infect Dis. 2021 Jul 1;73(1):e152-e157
pubmed: 32507892
Am J Respir Crit Care Med. 2018 Nov 15;198(10):1322-1330
pubmed: 29877739
Chest. 2017 Oct;152(4):800-809
pubmed: 28483608
Eur Respir J. 2019 Jul 11;54(1):
pubmed: 30880280
J Antimicrob Chemother. 2012 Apr;67(4):810-8
pubmed: 22290346
Antimicrob Agents Chemother. 1999 Dec;43(12):3001-4
pubmed: 10582897
J Infect Chemother. 2019 Feb;25(2):117-123
pubmed: 30447882
Front Microbiol. 2019 Aug 23;10:1977
pubmed: 31507579
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Jpn J Infect Dis. 2017 Jan 24;70(1):96-99
pubmed: 27000461
Clin Chest Med. 2015 Mar;36(1):13-34
pubmed: 25676516
J Clin Microbiol. 2014 Jan;52(1):251-9
pubmed: 24197885
Respir Med. 2018 Dec;145:14-20
pubmed: 30509703
Antimicrob Agents Chemother. 2014 Jul;58(7):4054-63
pubmed: 24798271
Int J Antimicrob Agents. 2011 Apr;37(4):296-301
pubmed: 21353489
Antimicrob Agents Chemother. 2015 Dec 07;60(2):1097-105
pubmed: 26643335
Eur Respir J. 2018 Mar 22;51(3):
pubmed: 29567726
Antimicrob Agents Chemother. 2019 Mar 27;63(4):
pubmed: 30745389
Ann Am Thorac Soc. 2017 Jan;14(1):49-56
pubmed: 27788025
Clin Infect Dis. 2017 Feb 1;64(3):309-316
pubmed: 28011608
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64
pubmed: 29054853

Auteurs

Keiji Fujiwara (K)

Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Department of Basic Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Fumiko Uesugi (F)

Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Koji Furuuchi (K)

Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Department of Basic Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Yoshiaki Tanaka (Y)

Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Takashi Yoshiyama (T)

Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Mikio Saotome (M)

Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Ken Ohta (K)

Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Satoshi Mitarai (S)

Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Department of Basic Mycobacteriosis, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Kozo Morimoto (K)

Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
Division of Clinical Research, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH